CN112961115A - Method and compound for preparing (E) -alpha-aryl-alpha, beta-unsaturated oxazoline or carboxylic acid - Google Patents

Method and compound for preparing (E) -alpha-aryl-alpha, beta-unsaturated oxazoline or carboxylic acid Download PDF

Info

Publication number
CN112961115A
CN112961115A CN202110221396.2A CN202110221396A CN112961115A CN 112961115 A CN112961115 A CN 112961115A CN 202110221396 A CN202110221396 A CN 202110221396A CN 112961115 A CN112961115 A CN 112961115A
Authority
CN
China
Prior art keywords
aryl
alpha
unsaturated
beta
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110221396.2A
Other languages
Chinese (zh)
Inventor
张磊
包王镇
潘文静
梁俞辰
彭勃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Normal University CJNU
Original Assignee
Zhejiang Normal University CJNU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Normal University CJNU filed Critical Zhejiang Normal University CJNU
Priority to CN202110221396.2A priority Critical patent/CN112961115A/en
Publication of CN112961115A publication Critical patent/CN112961115A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C07C57/60Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

The invention discloses a method for preparing (E) -alpha-aryl-alpha, beta-unsaturated oxazoline or carboxylic acid, which comprises the following steps: in the presence of TMSOTf and alkali, aryl high-valence iodine shown in a structural formula (I) and alpha, beta-unsaturated oxazoline shown in a structural formula (II) react in a solvent to synthesize (E) -alpha-aryl-alpha, beta-unsaturated oxazoline shown in a structural formula (III), and finally, the (E) -alpha, beta-unsaturated carboxylic acid shown in a structural formula (II) is obtained by hydrolysis under an acidic condition. The method synthesizes (E) -alpha-aryl-alpha, beta-unsaturated oxazoline under mild conditions by aryl high-valence iodine and alpha, beta-unsaturated oxazoline, and finally obtains (E) -alpha-aryl-alpha, beta-unsaturated carboxylic acid by hydrolysis under acidic conditions. The method has the advantages of mild reaction conditions, wide substrate application range, good selectivity, high yield, easy product separation and simple operation.

Description

Method and compound for preparing (E) -alpha-aryl-alpha, beta-unsaturated oxazoline or carboxylic acid
Technical Field
The invention belongs to the field of organic chemical synthesis, and particularly relates to a method and a compound for preparing (E) -alpha-aryl-alpha, beta-unsaturated oxazoline or carboxylic acid.
Background
Alpha-aryl-alpha, beta-unsaturated carbonyl building blocks are an important class of organic functional groups. The fragment is widely present in drugs and natural products. For example, cocaldehyde in perfume cosmetics, glycitein, perampanel, isoflavone, and luteolin, a natural product of anti-inflammatory and antiviral drugs, all contain α -aryl- α, β -unsaturated carbonyl fragments. Therefore, the synthesis of α -aryl- α, β -unsaturated carbonyl groups is one of the important research targets of synthetic chemistry.
Conventional α -aryl- α, β -unsaturated carbonyl compounds require synthesis through multiple reactions. For example, alpha-halogen (or metal) -alpha, beta-unsaturated carbonyl compounds are synthesized by nucleophilic substitution reaction, and then coupled with aromatic hydrocarbon metal reagent or halogenated aromatic hydrocarbon to obtain alpha-aryl-alpha, beta-unsaturated carbonyl compounds (J.Org.chem.2006,71, 5743-5747; tetrahedron.1997,53, 16711-16720). In addition, in 2009, chengweiwu project group reported that the synthesis of α -aryl- α, β -unsaturated carbonyl compounds was achieved using benzyl bromide and α -aryldiazoacetic acid methyl ester under palladium catalysis (org. lett.2009,11, 469-. This reaction also has the problem that the diazo starting material is not readily available.
In 2004, the Krische group discovered that arylation of α -C-H bond of 2-cyclohexen-1-one (or 2-cyclopenten-1-one) could be achieved using tributylphosphine as a catalyst and aryl bismuth as an arylating agent (j.am. chem. soc.2004,126, 5350-5351.). Although the reaction conditions are mild and the selectivity is excellent, the reaction needs an organic bismuth reagent which is not easy to obtain, and the application range of the substrate is narrow.
Wangwen adopts a strategy of organic small molecule catalysis in 2011 to realize the alpha-C-H bond arylation reaction of alpha, beta-unsaturated aldehyde (nat. Commun.2011,2, 524-534.). The reaction does not need metal participation, is environment-friendly and has high selectivity, but the reaction is only suitable for aromatic hydrocarbon substrates with electron-withdrawing functional groups.
In summary, the α -C-H bond arylation of α, β -unsaturated carbonyl compounds is still a problem to be solved in synthetic chemistry.
Disclosure of Invention
In order to overcome the defects in the prior art, the invention provides a novel method for preparing (E) -alpha-aryl-alpha, beta-unsaturated oxazoline or (E) -alpha-aryl-alpha, beta-unsaturated carboxylic acid, and the method has the advantages of mild reaction conditions, wide substrate application range, good selectivity, higher yield, easy product separation, simple operation and the like.
The invention also provides a (E) -alpha-aryl-alpha, beta-unsaturated oxazoline or (E) -alpha-aryl-alpha, beta-unsaturated carboxylic acid compound, and various important derivative compounds can be obtained by utilizing the compounds; and the above (E) -alpha-aryl-alpha, beta-unsaturated oxazoline or (E) -alpha-aryl-alpha, beta-unsaturated carboxylic acid itself can be sold as an important organic intermediate.
The technical scheme adopted by the invention is as follows:
a method for preparing (E) -alpha-aryl-alpha, beta-unsaturated carboxylic acid comprises the steps of reacting aryl high-valence iodine shown in a structural formula (I) with alpha, beta-unsaturated oxazoline shown in a structural formula (II) in a solvent in the presence of an activating agent (preferably TMSOTf, namely trimethylsilyl trifluoromethanesulfonate) and alkali to synthesize (E) -alpha-aryl-alpha, beta-unsaturated oxazoline shown in a structural formula (III), and finally hydrolyzing under an acidic condition to obtain the (E) -alpha, beta-unsaturated carboxylic acid shown in the structural formula (II). The general formula of the reaction is as follows:
Figure BDA0002955233640000021
wherein R is1Selected from hydrogen, halogen, alkyl, alkoxy, substituted alkoxy, amido or aryl, heteroaryl; r1Represents one or more substituents substituted on the aromatic ring in the above formula, and the substituents are independent of each other, and may be the same or different; r2Selected from hydrogen, alkyl, cycloalkyl and aryl.
The mechanism of the reaction is shown below:
Figure BDA0002955233640000031
we have constructed, by means of the MBH reaction, a rearrangement precursor IM of our [3,3] -sigma rearrangement reaction, thus developing an "assembly/addition" type of [3,3] -sigma rearrangement reaction. Specifically, the rearrangement reaction is carried out in four stages, including: (1) electrophilic 'assembly' of activated aryl hypervalent iodine with alpha, beta unsaturated oxazoline; (2) introducing Lewis base to carry out 1, 4-addition to construct an enol salt type intermediate IM; (3) carrying out [3,3] -rearrangement and aromatization on the intermediate IM; (4) elimination by β -H gives a product, thereby effecting MBH type [3,3] - σ rearrangement reactions. Finally hydrolyzing the rearrangement product under acidic condition to obtain (E) -alpha, beta-unsaturated carboxylic acid
Preferably, in the structural formulae (I) to (IV), R1Selected from hydrogen, halogen, C1~C4Alkyl radical, C1~C3Alkoxy, substituted C1~C3Alkoxy, amido or heteroaryl; r2Selected from hydrogen, C1~C4Alkyl radical, C3~C6Cycloalkyl and aryl. As a particularly preferred embodiment, said R1Selected from hydrogen, cyanomethoxy, methyl; r1Selected from hydrogen, methyl, ethyl, propyl, and the like.
Preferably, the feeding molar ratio of the aryl high-valence iodine to an activating agent (preferably TMSOTf) is 1: 1-2; as a further preference, the aryl hypervalent iodine to activator (preferably TMSOTf) feed molar ratio is 1: 2.
Preferably, the feeding molar ratio of the aryl high-valence iodine to the alpha, beta-unsaturated oxazoline is 1: 1-2; more preferably, the molar ratio of the aryl higher iodine to the alpha, beta-unsaturated oxazoline is 1: 2.
Preferably, the feeding molar ratio of the activating agent (preferably TMSOTf) to the Lewis base is 1: 1.1-2; as a further preference, the activator (preferably TMSOTf) is dosed in a molar ratio to lewis base of 1: 2.
The solvent used in the present invention is dichloromethane.
The Lewis base used in the present invention is a tertiary amine or a pyridine base, preferably 4-methylpyridine.
The reaction temperature is-80-0 ℃, and the reaction time is 12-36 h; the reaction temperature is preferably-80 to-10 ℃ and the reaction time is 24 hours.
Preferably, the acid used for hydrolysis is hydrochloric acid or sulfuric acid or an aqueous solution of the above acid, and more preferably, the acid used for hydrolysis is HCl (3.5M) or H2SO4(4M)/dioxane(1/1)。
In the present invention, the configuration of the product is E formula.
Compared with the prior art, the method synthesizes (E) -alpha-aryl-alpha, beta-unsaturated oxazoline under mild conditions by aryl high-valence iodine and an alpha, beta-unsaturated oxazoline compound, and then synthesizes (E) -alpha-aryl-alpha, beta-unsaturated carboxylic acid by hydrolysis, and has the advantages that: the advantages are that:
(1) the method has the advantages of mild reaction conditions, wide substrate application range, good selectivity, high yield, easy product separation and simple operation;
(2) the raw materials used in the method are cheap and easy to obtain, and the defects that the traditional method uses an organic metal reagent, the reaction condition requirements are strict, and the reaction substrate is limited are avoided;
(3) no matter the configuration of the raw material alpha, beta-unsaturated oxazoline is Z formula or E formula, the product is a single E formula, and a new reaction strategy is provided for the synthesis of (E) -alpha-aryl-alpha, beta-unsaturated carboxylic acid.
Drawings
FIG. 1 is a NOE spectrum of the product obtained in example 2.
FIG. 2 is a NOE spectrum of the product obtained in example 3.
FIG. 3 is a NOE spectrum of the product obtained in example 5.
FIG. 4 is a single crystal diagram of the product obtained in example 6, which was subjected to X-ray test.
Detailed Description
Example 1
Figure BDA0002955233640000041
TMSOTf (181. mu.L, 1.0mmol) was added to a solution of iodobenzene diacetate (161mg,0.5mmol) in DCM (5mL) at-78 deg.C, and after stirring for 15min, the mixture was added to an α, β -unsaturated oxazoline compound represented by the above formulaSubstance (97.1mg,1.0 mmol). After stirring for 15min, 4-methylpyridine (93mg, 1.0mmol) was added. Then gradually heating to-10 ℃, continuing to react for 24h, and then adding saturated NaHCO3The reaction was quenched with aqueous solution (5mL) and extracted with DCM (10 mL. times.3). The organic phase is passed through anhydrous Na2SO4After drying, concentration and purification by column chromatography (Rf 0.32, developing solvent: petroleum ether/ethyl acetate 2/1, v/v) gave the product 2- (1- (2-iodophenyl) vinyl) -oxazoline as a colorless oily liquid, 106.2mg, 71% yield.
1H NMR(600MHz,CDCl3):δ7.86(dd,J=7.9,0.9Hz,1H),7.37–7.34(m,1H),7.31–7.26(m,1H),7.03–7.00(m,1H),6.27(s,1H),5.61(s,1H),4.38(t,J=9.5Hz,2H),3.97(t,J=9.5Hz,2H).
13C NMR(151MHz,CDCl3):δ163.7,143.3,140.8,139.2,130.1,129.5,128.2,125.5,98.9,67.8,55.6.
IR(neat):3048,2927,2873,2170,1646,1601,1178,725.
HRMS(ESI-TOF):calculated for[C11H11INO(M+H+)]:299.9880,found:299.9882.
Example 2
Figure BDA0002955233640000051
TMSOTf (181. mu.L, 1.0mmol) was added to a solution of iodobenzene diacetate (161mg,0.5mmol) in DCM (5mL) at-78 deg.C, and after stirring for 15min, the α, β -unsaturated oxazoline compound (111.1mg,1.0mmol) represented by the above formula was added to the mixture. After stirring for 15min, 4-methylpyridine (93mg, 1.0mmol) was added. Then gradually heating to-10 ℃, continuing to react for 24h, and then adding saturated NaHCO3The reaction was quenched with aqueous solution (5mL) and extracted with DCM (10 mL. times.3). The organic phase is passed through anhydrous Na2SO4After drying, concentration and purification by column chromatography (Rf 0.37, developing solvent: petroleum ether/ethyl acetate 2/1, v/v) gave the product (E) -2- (1- (2-iodophenyl) prop-1-en-1-yl) -oxazoline as a colorless oily liquid, 112.7mg, 72% yield.
1H NMR(600MHz,CDCl3):δ7.88(d,J=7.9Hz,1H),7.38–4.35(m,1H),7.17(dd,J=7.6,1.5Hz,1H),7.03–6.98(m,1H),6.84(q,J=7.0Hz,1H),4.38–4.26(m,2H),3.94–3.89(m,2H),1.60(d,J=7.1Hz,3H).
13C NMR(151MHz,CDCl3):δ164.2,141.3,139.2,136.3,134.2,130.4,129.2,128.3,100.0,67.5,55.3,15.3.
IR(neat):3053,2940,2888,2872,2283,1916,1618,753.
HRMS(ESI-TOF):calculated for[C12H13INO(M+H+)]:314.0036,found:314.0036.
FIG. 1 is the NOE spectrum of the product, confirming the product configuration as E configuration.
Example 3
Figure BDA0002955233640000061
TMSOTf (181. mu.L, 1.0mmol) was added to a solution of iodobenzene diacetate (161mg,0.5mmol) in DCM (5mL) at-78 deg.C, and after stirring for 15min, the α, β -unsaturated oxazoline compound (139.2mg,1.0mmol) represented by the above formula was added to the mixture. After stirring for 15min, 4-methylpyridine (93mg, 1.0mmol) was added. Then gradually heating to-10 ℃, continuing to react for 24h, and then adding saturated NaHCO3The reaction was quenched with aqueous solution (5mL) and extracted with DCM (10 mL. times.3). The organic phase is passed through anhydrous Na2SO4After drying, concentration and purification by column chromatography (Rf 0.27, developing solvent: petroleum ether/ethyl acetate 2/1, v/v) gave the product (E) -2- (1- (2-iodophenyl) pent-1-en-1-yl) -oxazoline as a colorless oily liquid 117.7mg, 69% yield.
1H NMR(600MHz,CDCl3):δ7.87(dd,J=8.0,1.1Hz,1H),7.37–7.34(m,1H),7.16(dd,J=7.6,1.7Hz,1H),7.01–6.99(m,1H),6.76(t,J=7.6Hz,1H),4.37–4.25(m,2H),3.93–3.89(m,2H),1.97–1.83(m,2H),1.50–1.39(m,2H),0.87(t,J=7.4Hz,3H).
13C NMR(151MHz,CDCl3):δ164.0,141.5,141.2,139.0,133.1,130.2,129.1,128.0,100.1,67.3,55.2,31.4,21.7,14.0.
IR(neat):3053,2954,2888,2870,1916,1618,988,753.
HRMS(ESI-TOF):calculated for[C14H17INO(M+H+)]:342.0349,found:342.0347.
FIG. 2 is the NOE spectrum of the product, the product configuration being identified as the E configuration.
Example 4
Figure BDA0002955233640000071
TMSOTf (181. mu.L, 1.0mmol) was added to a solution of iodobenzene diacetate (161mg,0.5mmol) in DCM (5mL) at-78 deg.C, and after stirring for 15min, the α, β -unsaturated oxazoline compound (139.2mg,1.0mmol) represented by the above formula was added to the mixture. After stirring for 15min, 4-methylpyridine (93mg, 1.0mmol) was added. Then gradually heating to-10 ℃, continuing to react for 24h, and then adding saturated NaHCO3The reaction was quenched with aqueous solution (5mL) and extracted with DCM (10 mL. times.3). The organic phase is passed through anhydrous Na2SO4After drying, concentration and purification by column chromatography (Rf 0.27, developing solvent: petroleum ether/ethyl acetate 2/1, v/v) gave the product (E) -2- (1- (2-iodophenyl) pent-1-en-1-yl) -oxazoline as a colorless oily liquid, 116.0mg, in 68% yield.
1H NMR(600MHz,CDCl3):δ7.87(dd,J=8.0,1.1Hz,1H),7.37–7.34(m,1H),7.16(dd,J=7.6,1.7Hz,1H),7.01–6.99(m,1H),6.76(t,J=7.6Hz,1H),4.37–4.25(m,2H),3.93–3.89(m,2H),1.97–1.83(m,2H),1.50–1.39(m,2H),0.87(t,J=7.4Hz,3H).
13C NMR(151MHz,CDCl3):δ164.0,141.5,141.2,139.0,133.1,130.2,129.1,128.0,100.1,67.3,55.2,31.4,21.7,14.0.
IR(neat):3053,2954,2888,2870,1916,1618,988,753.
HRMS(ESI-TOF):calculated for[C14H17INO(M+H+)]:342.0349,found:342.0347.
Example 5
Figure BDA0002955233640000072
TMSOTf (181. mu.L, 1.0mmol) was added to a solution of iodobenzene diacetate (161mg,0.5mmol) in DCM (5mL) at-78 deg.C, and after stirring for 15min, the α, β -unsaturated oxazoline compound (179.3mg,1.0mmol) represented by the above formula was added to the mixture. After stirring for 15min, 4-methylpyridine (93mg, 1.0mmol) was added. Then gradually heating to-10 ℃, continuing to react for 24h, and then adding saturated NaHCO3The reaction was quenched with aqueous solution (5mL) and extracted with DCM (10 mL. times.3). The organic phase is passed through anhydrous Na2SO4After drying, concentration and purification by column chromatography (Rf 0.53, developing solvent: petroleum ether/ethyl acetate 2/1, v/v) gave the product (E) -2- (2-cyclohexyl-1- (2-iodophenyl) vinyl) -oxazoline as a colorless oily liquid, 106.6mg, 56% yield.
FIG. 3 is the NOE spectrum of the product, with the product configuration identified as the E configuration.
Example 6
Figure BDA0002955233640000081
TMSOTf (181. mu.L, 1.0mmol) was added to a solution of aryl hypervalent iodine (188.5mg,0.5mmol) represented by the above formula in DCM (5mL) at-78 deg.C, and after stirring for 15min, the α, β -unsaturated oxazoline compound (111.1mg,1.0mmol) represented by the above formula was added to the mixture. After stirring for 15min, 4-methylpyridine (93mg, 1.0mmol) was added. Then gradually heating to-10 ℃, continuing to react for 24h, and then adding saturated NaHCO3The reaction was quenched with aqueous solution (5mL) and extracted with DCM (10 mL. times.3). The organic phase is passed through anhydrous Na2SO4After drying, concentration and purification by column chromatography (Rf 0.16, developing solvent: petroleum ether/ethyl acetate 2/1, v/v) gave the product (E) -2- (4- (1- (azolin-2-yl) prop-1-en-1-yl) -3-iodophenoxy) acetonitrile as a white solid in 149.1mg, 81% yield. (and further define its structure by X-ray)
1H NMR(600MHz,CDCl3):δ7.48(d,J=2.6Hz,1H),7.12(d,J=8.4Hz,1H),7.01–6.99(m,1H),6.84(q,J=7.1Hz,1H),4.72(s,2H),4.37–4.27(m,2H),3.92–3.88(m,2H),1.61(d,J=7.1Hz,3H).
13C NMR(151MHz,CDCl3):δ164.2,155.9,136.9,136.2,133.2,131.0,125.5,114.9,100.2,67.5,55.2,53.7,15.3.
IR(neat):3312,2921,2159,2011,1715,1610,1510,990,749.
HRMS(ESI-TOF):calculated for[C14H13IN2O2Na(M+Na+)]:390.9914,found:390.9931.
We performed X-ray tests on the product obtained in this example, as shown in FIG. 4, further verifying the structure of formula E.
Example 7
Figure BDA0002955233640000091
TMSOTf (181. mu.L, 1.0mmol) was added to a solution of aryl hypervalent iodine (175mg,0.5mmol) represented by the above formula in DCM (5mL) at-78 deg.C, and after stirring for 15min, the α, β -unsaturated oxazoline compound (111.1mg,1.0mmol) represented by the above formula was added to the mixture. After stirring for 15min, 4-methylpyridine (93mg, 1.0mmol) was added. Then gradually heating to-10 ℃, continuing to react for 24h, and then adding saturated NaHCO3The reaction was quenched with aqueous solution (5mL) and extracted with DCM (10 mL. times.3). The organic phase is passed through anhydrous Na2SO4After drying, concentration and purification by column chromatography (Rf 0.38, developing solvent: petroleum ether/ethyl acetate 2/1, v/v) gave the product (E) -2- (1- (2-iodo-3, 4-dimethylphenyl) prop-1-en-1-yl) -oxazoline as a white solid in 141.6mg, 83% yield.
1H NMR(600MHz,CDCl3):δ7.12(d,J=7.6Hz,1H),6.88(d,J=7.6Hz,1H),6.81(q,J=7.1Hz,1H),4.38–4.26(m,2H),3.92–3.89(m,2H),2.48(s,3H),2.35(s,3H),1.59(d,J=7.1Hz,3H).
13C NMR(151MHz,CDCl3):δ164.4,140.3,139.9,136.3,135.7,135.5,129.8,127.3,108.3,67.4,55.3,26.3,22.0,15.2.
IR(neat):3288,2933,2857,2111,1670,1611,1094,989
HRMS(ESI-TOF):calculated for[C14H16INONa(M+Na+)]:364.0169,found:364.0182.
Example 8
Figure BDA0002955233640000092
2- (1- (2-iodophenyl) vinyl) -4, 5-dihydrooxazoline (1.88g, 6.3mmol) was dissolved in 3.5M HCl (100mL), stirred at 80 ℃ for 15h, cooled to room temperature, and concentrated. Extracting with DCM, and extracting the organic phase with anhydrous Na2SO4After drying, concentration was carried out to give 2- (2-iodophenyl) acrylic acid (CAS: 2353621-35-7) as a white solid, 1.69g, yield 98%. (Rf 0.28, developing solvent: dichloromethane/methanol 15/1).
1H NMR(600MHz,CDCl3):δ7.86(d,J=7.9Hz,1H),7.37(dd,J=10.8,4.1Hz,1H),7.26–7.23(m,1H),7.06–7.03(m,1H),6.67(s,1H),5.87(s,1H).
13C NMR(151MHz,CDCl3):δ170.2,144.1,142.0,139.1,131.5,130.3,129.8,128.3,98.9.
IR(neat):2923,1931,1685,1611,1418,1256,1219,1012,728.
HRMS(ESI-TOF):calculated for[C9H6IO2(M–H+)]:272.9418,found:272.9428.
Example 9
Figure BDA0002955233640000101
(E) -2- (1- (2-iodophenyl) propenyl) -4, 5-dihydrooxazoline (2.07g, 6.6mmol) was dissolved in H2SO4(4M)/dioxane (1/1,28mL), stirred at 90 ℃ for 18h, cooled to room temperature, neutralized with sodium hydroxide solution (2M), and concentrated. After dissolution in DCM, pH 1 was adjusted with hydrochloric acid (1M), then extracted with DCM and the organic phase with anhydrous Na2SO4After drying, concentration gave (E) -2- (2-iodophenyl) but-2-enoic acid as a white solid, 1.86g, 98% yield. (Rf 0.28, developing solvent: dichloromethane/methanol 15/1).

Claims (10)

1. A preparation method of (E) -alpha-aryl-alpha, beta-unsaturated oxazoline or carboxylic acid is characterized in that aryl hypervalent iodine shown in a structural formula (I) and alpha, beta-unsaturated oxazoline shown in a structural formula (II) react in a solvent in the presence of an activating agent and alkali to obtain (E) -alpha-aryl-alpha, beta-unsaturated oxazoline shown in a structural formula (III); optionally further hydrolyzing the (E) -alpha-aryl-alpha, beta-unsaturated oxazoline represented by the structural formula (III) to obtain the (E) -alpha-aryl-alpha, beta-unsaturated carboxylic acid.
Figure FDA0002955233630000011
Wherein R is1Selected from hydrogen, halogen, alkyl, alkoxy, substituted alkoxy, amino, amido or aryl, heteroaryl, R1Is one or more; r2Selected from hydrogen, alkyl, cycloalkyl and aryl.
2. The method for producing (E) - α -aryl- α, β -unsaturated oxazoline or carboxylic acid according to claim 1, wherein R is R1Selected from hydrogen, halogen, C1~C4Alkyl radical, C1~C3Alkoxy, substituted C1~C3Alkoxy, amido or heteroaryl; r2Selected from hydrogen, C1~C4Alkyl radical, C3~C6Cycloalkyl and aryl.
3. The method for producing an (E) - α -aryl- α, β -unsaturated oxazoline or carboxylic acid according to claim 1, wherein the molar ratio of the aryl hypervalent iodine to the activator is 1:1 to 2.
4. The method for producing an (E) - α -aryl- α, β -unsaturated oxazoline or carboxylic acid according to claim 1, wherein the molar ratio of the aryl higher iodine to the α, β -unsaturated oxazoline is 1:1 to 2.
5. The process for producing (E) - α -aryl- α, β -unsaturated oxazoline or carboxylic acid according to claim 1, wherein the base is a tertiary amine; the feeding molar ratio of the activating agent to the alkali is 1: 1.1-2.
6. The process for producing (E) - α -aryl- α, β -unsaturated oxazoline or carboxylic acid according to claim 1, wherein the solvent is methylene chloride; the activating agent is trimethylsilyl trifluoromethanesulfonate; the alkali is tertiary amine or pyridine alkali.
7. The method for producing (E) - α -aryl- α, β -unsaturated oxazoline or carboxylic acid according to claim 1, wherein the reaction temperature of the aryl hypervalent iodine with the α, β -unsaturated oxazoline is from-80 to 0 ℃ and the reaction time is from 12 to 36 hours.
8. The process for producing (E) - α -aryl- α, β -unsaturated oxazoline or carboxylic acid as claimed in claim 1, wherein the acid used for the hydrolysis is hydrochloric acid or sulfuric acid.
9. An (E) - α -aryl- α, β -unsaturated oxazoline having a structure represented by the structural formula (III):
Figure FDA0002955233630000021
wherein R is1Selected from hydrogen, halogen, alkyl, alkoxy, substituted alkoxy, amino, amido or aryl, heteroaryl, R1Is one or more; r2Selected from hydrogen, alkyl, cycloalkyl and aryl.
10. An (E) - α -aryl- α, β -unsaturated carboxylic acid having the structure of formula (IV):
Figure FDA0002955233630000022
wherein R is1Selected from hydrogen, halogen, alkyl, alkoxy, substituted alkoxy, amino, amido or aryl, heteroaryl, R1Is one or more; r2Selected from hydrogen, alkyl, cycloalkyl and aryl.
CN202110221396.2A 2021-02-27 2021-02-27 Method and compound for preparing (E) -alpha-aryl-alpha, beta-unsaturated oxazoline or carboxylic acid Pending CN112961115A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110221396.2A CN112961115A (en) 2021-02-27 2021-02-27 Method and compound for preparing (E) -alpha-aryl-alpha, beta-unsaturated oxazoline or carboxylic acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110221396.2A CN112961115A (en) 2021-02-27 2021-02-27 Method and compound for preparing (E) -alpha-aryl-alpha, beta-unsaturated oxazoline or carboxylic acid

Publications (1)

Publication Number Publication Date
CN112961115A true CN112961115A (en) 2021-06-15

Family

ID=76275858

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110221396.2A Pending CN112961115A (en) 2021-02-27 2021-02-27 Method and compound for preparing (E) -alpha-aryl-alpha, beta-unsaturated oxazoline or carboxylic acid

Country Status (1)

Country Link
CN (1) CN112961115A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114773285A (en) * 2022-03-25 2022-07-22 大连理工大学 Efficient preparation method of alpha-amino oxazoline compound

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105566021A (en) * 2015-12-30 2016-05-11 中国科学技术大学 Preparation method of alpha, beta-unsaturated carboxylic acid compounds
CN109776295A (en) * 2019-02-18 2019-05-21 浙江师范大学 A kind of aryl iodine compound and preparation method of the ortho position containing difluoro methylene
CN109824501A (en) * 2019-02-18 2019-05-31 浙江师范大学 A kind of the aryl iodine compound and preparation method of ortho position difluoro methylene containing carboxylic

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105566021A (en) * 2015-12-30 2016-05-11 中国科学技术大学 Preparation method of alpha, beta-unsaturated carboxylic acid compounds
CN109776295A (en) * 2019-02-18 2019-05-21 浙江师范大学 A kind of aryl iodine compound and preparation method of the ortho position containing difluoro methylene
CN109824501A (en) * 2019-02-18 2019-05-31 浙江师范大学 A kind of the aryl iodine compound and preparation method of ortho position difluoro methylene containing carboxylic

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JUNSONG TIAN ET AL.: "Selective ortho C-H Cyanoalkylation of (Diacetoxyiodo)arenes through [3,3]-Sigmatropic Rearrangement", 《ANGEW.CHEM.INT.ED.》 *
包王镇: "芳基高价碘参与的Morita-Baylis-Hillman型[3,3]-σ重排反应", 《中国优秀博硕士学位论文全文数据库(硕士)工程科技Ⅰ辑》 *
彭勃 等: "芳基高价碘与烯丙基硅烷的[3,3]-重排反应研究进展", 《浙江师范大学学报(自然科学版)》 *
彭勃 等: "芳基高价碘的邻位炔丙基化和氰烷基化反应进展", 《浙江师范大学学报( 自然科学版)》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114773285A (en) * 2022-03-25 2022-07-22 大连理工大学 Efficient preparation method of alpha-amino oxazoline compound

Similar Documents

Publication Publication Date Title
CN110117260B (en) Preparation method of 3-alkyl quinoxaline-2 (1H) -ketone compound
CN114634482B (en) Diazonium difluoro methylation reagent and synthetic method and application thereof
CN107382820B (en) Synthetic method of 3-aryl isoindole derivative
CN114478375B (en) Preparation method of 3-alkenyl quinoline-2 (1H) ketone derivative
Shi et al. Ethyl 3-Fluoro-3-(tributylstannyl)-2-methoxyacrylate: Preparation and Palladium/Copper-Cocatalyzed Cross-Coupling Reactions as a Novel Route to. beta.-Fluoro-. alpha.-keto Acid Derivatives
CN108409628B (en) Preparation method of alpha-aryl nitrile compound
CN112961115A (en) Method and compound for preparing (E) -alpha-aryl-alpha, beta-unsaturated oxazoline or carboxylic acid
Crisp et al. Heck couplings of non-activated alkenes
JP3771128B2 (en) Novel synthesis method of febrifugine and febrifugine compounds
CN115215814A (en) Synthetic method of isoxazolidine compounds
CN111362795B (en) Preparation method of substituted butyrate derivatives
CN109942615B (en) Aryl amine derivative containing alkynyl and preparation method and application thereof
CN113979918A (en) C-3-position five-membered spiro indolone derivative containing all-carbon tetra-substituted olefin structure and preparation and application thereof
CN108727179B (en) Synthetic method of alpha-allyl substituted alpha, beta-unsaturated ketone, ester or nitrile compound
CN106279014A (en) A kind of synthesis phenylglycine analog derivative and method
CN108864173B (en) Process for converting substituted sodium arylsulfinates into aryltri-n-butyltin
CN107382899B (en) Polysubstituted 2-hydroxy-1, 4-benzoxazine derivative
CN111138350A (en) Asymmetric synthesis method of dexchlorpheniramine and dexbrompheniramine
CN113845481B (en) Synthesis method of 4, 4-dimethyl-4, 5-dihydropyridazin-3-one
CN116023357B (en) Method for converting o-hydroxyacetophenone into quaternary carbon center-containing chromanone compound
RU2522460C1 (en) Method of producing alkenyl anthraquinones
CN117430542B (en) Synthesis method of trifluoromethyl indole derivative
CN115433097B (en) Method for preparing 4-butoxybenzoic acid (2-diethylaminoethyl) ester without metal
CN113200891B (en) Preparation method of cis-N-styryl amide derivative
CN109232340B (en) Method for preparing 3-amino-2-thiocyano-alpha, beta-unsaturated compound

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210615

WD01 Invention patent application deemed withdrawn after publication